Business Context and Reporting Period
This Form 8-K Current Report was filed by CareDx, Inc. (CDNA) on March 9, 2024, with the earliest event reported on that date. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and committee chairperson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments and compensation arrangements rather than financial performance results.
Material Changes
The material change reported is the appointment of R. Bryan Riggsbee as a Class II director, effective March 11, 2024. Mr. Riggsbee was also appointed as the Chairperson of the Audit and Finance Committee. He brings significant experience as a former CFO of Myriad Genetics and a former Senior Vice President of Corporate Finance at LabCorp.
Compensation and Governance Details
Mr. Riggsbee's compensation package includes:
- Cash Retainers: $45,000 annually for Board service and $20,000 annually for Audit Committee Chair service, payable quarterly.
- Initial Equity Grants: Contingent on shareholder approval of a new equity incentive plan, he will receive stock options and restricted stock units (RSUs) each with a grant date fair value of $100,000. Options vest monthly over three years; RSUs vest in three equal annual installments.
- Annual Equity Grants: Under current policy, he will receive annual automatic grants of options and RSUs each with a grant date fair value of $150,000. Options vest monthly over one year; RSUs vest in one installment on the first anniversary.
An indemnification agreement was also executed with Mr. Riggsbee. No related party transactions were reported.
Investor Verification Checklist
- Verify the shareholder approval status of the new equity incentive plan required to trigger Mr. Riggsbee's initial $200,000 equity grant.
- Review the press release filed as Exhibit 99.1 for additional context on the Board's strategic direction.
- Confirm the exact vesting schedules and share counts once the grant date fair value is converted to shares.